NBIX logo

Neurocrine Biosciences (NBIX) Long term liabilities

Annual long term liabilities:

$621.30M+$256.70M(+70.41%)
December 31, 2024

Summary

  • As of today (May 29, 2025), NBIX annual total long term liabilities is $621.30 million, with the most recent change of +$256.70 million (+70.41%) on December 31, 2024.
  • During the last 3 years, NBIX annual long term liabilities has risen by +$168.60 million (+37.24%).
  • NBIX annual long term liabilities is now at all-time high.

Performance

NBIX Long term liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNBIXbalance sheet metrics

quarterly long term liabilities:

$629.10M+$7.80M(+1.26%)
March 31, 2025

Summary

  • As of today (May 29, 2025), NBIX quarterly total long term liabilities is $629.10 million, with the most recent change of +$7.80 million (+1.26%) on March 31, 2025.
  • Over the past year, NBIX quarterly long term liabilities has increased by +$255.70 million (+68.48%).
  • NBIX quarterly long term liabilities is now at all-time high.

Performance

NBIX quarterly long term liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNBIXbalance sheet metrics

Long term liabilities Formula

Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities

NBIX Long term liabilities Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+70.4%+68.5%
3 y3 years+37.2%+25.9%
5 y5 years+498.6%+20.7%

NBIX Long term liabilities Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+404.3%at high+453.3%
5 y5-yearat high+498.6%at high+620.6%
alltimeall timeat high>+9999.0%at high>+9999.0%

NBIX Long term liabilities History

DateAnnualQuarterly
Mar 2025
-
$629.10M(+1.3%)
Dec 2024
$621.30M(+70.4%)
$621.30M(+60.8%)
Sep 2024
-
$386.40M(-2.7%)
Jun 2024
-
$397.30M(+6.4%)
Mar 2024
-
$373.40M(+2.4%)
Dec 2023
$364.60M(+195.9%)
$364.60M(+136.0%)
Sep 2023
-
$154.50M(-13.0%)
Jun 2023
-
$177.60M(-41.0%)
Mar 2023
-
$301.20M(+144.5%)
Dec 2022
$123.20M(-72.8%)
$123.20M(+8.4%)
Sep 2022
-
$113.70M(-61.7%)
Jun 2022
-
$296.60M(-40.7%)
Mar 2022
-
$499.90M(+10.4%)
Dec 2021
$452.70M(+7.3%)
$452.70M(+1.6%)
Sep 2021
-
$445.40M(-4.1%)
Jun 2021
-
$464.30M(+3.0%)
Mar 2021
-
$450.80M(+6.8%)
Dec 2020
$422.00M(+306.6%)
$422.00M(+383.4%)
Sep 2020
-
$87.30M(-21.6%)
Jun 2020
-
$111.40M(-78.6%)
Mar 2020
-
$521.30M(+402.2%)
Dec 2019
$103.80M(-75.5%)
$103.80M(-78.8%)
Sep 2019
-
$489.77M(+1.5%)
Jun 2019
-
$482.57M(+1.3%)
Mar 2019
-
$476.44M(+12.3%)
Dec 2018
$424.15M(+8.5%)
$424.15M(+1321.8%)
Sep 2018
-
$29.83M(-92.6%)
Jun 2018
-
$402.12M(+1.7%)
Mar 2018
-
$395.41M(+1.1%)
Dec 2017
$391.03M(+1875.4%)
$391.03M(+1.1%)
Sep 2017
-
$386.84M(+1.5%)
Jun 2017
-
$381.13M(+1942.5%)
Mar 2017
-
$18.66M(-5.7%)
Dec 2016
$19.80M(-19.6%)
$19.80M(-5.0%)
Sep 2016
-
$20.84M(-4.8%)
Jun 2016
-
$21.90M(-5.2%)
Mar 2016
-
$23.10M(-6.2%)
Dec 2015
$24.62M(+31.8%)
$24.62M(-4.1%)
Sep 2015
-
$25.67M(-3.9%)
Jun 2015
-
$26.71M(-4.1%)
Mar 2015
-
$27.86M(+49.2%)
Dec 2014
$18.67M(-17.3%)
$18.67M(-5.1%)
Sep 2014
-
$19.67M(-4.7%)
Jun 2014
-
$20.64M(-4.6%)
Mar 2014
-
$21.63M(-4.1%)
Dec 2013
$22.57M(-13.1%)
$22.57M(-3.4%)
Sep 2013
-
$23.35M(-3.6%)
Jun 2013
-
$24.22M(-3.5%)
Mar 2013
-
$25.09M(-3.3%)
Dec 2012
$25.96M(-16.7%)
$25.96M(-3.2%)
Sep 2012
-
$26.83M(-4.9%)
Jun 2012
-
$28.20M(-5.0%)
Mar 2012
-
$29.68M(-4.8%)
Dec 2011
$31.18M(-56.9%)
$31.18M(-27.2%)
Sep 2011
-
$42.84M(-17.4%)
Jun 2011
-
$51.86M(-16.3%)
Mar 2011
-
$61.98M(-14.3%)
Dec 2010
$72.30M
$72.30M(-9.7%)
DateAnnualQuarterly
Sep 2010
-
$80.10M(-11.5%)
Jun 2010
-
$90.51M(+103.2%)
Mar 2010
-
$44.53M(-5.1%)
Dec 2009
$46.90M(-15.2%)
$46.90M(-7.7%)
Sep 2009
-
$50.79M(+9.2%)
Jun 2009
-
$46.50M(-5.8%)
Mar 2009
-
$49.38M(-10.7%)
Dec 2008
$55.31M(-56.8%)
$55.31M(-55.8%)
Sep 2008
-
$125.11M(-1.0%)
Jun 2008
-
$126.33M(-0.7%)
Mar 2008
-
$127.25M(-0.6%)
Dec 2007
$128.05M(+133.5%)
$128.05M(+143.8%)
Sep 2007
-
$52.52M(-2.5%)
Jun 2007
-
$53.87M(-0.6%)
Mar 2007
-
$54.19M(-1.2%)
Dec 2006
$54.84M(-7.6%)
$54.84M(-2.7%)
Sep 2006
-
$56.39M(-0.8%)
Jun 2006
-
$56.84M(-6.5%)
Mar 2006
-
$60.82M(+2.5%)
Dec 2005
$59.33M(-9.8%)
$59.33M(-4.6%)
Sep 2005
-
$62.19M(-1.6%)
Jun 2005
-
$63.20M(-2.0%)
Mar 2005
-
$64.47M(-2.0%)
Dec 2004
$65.81M(+22.3%)
$65.81M(-3.1%)
Sep 2004
-
$67.94M(+0.8%)
Jun 2004
-
$67.44M(+24.1%)
Mar 2004
-
$54.33M(+0.9%)
Dec 2003
$53.82M(+448.9%)
$53.82M(+7.0%)
Sep 2003
-
$50.30M(-17.8%)
Jun 2003
-
$61.18M(+20.6%)
Mar 2003
-
$50.75M(+417.5%)
Dec 2002
$9.81M(-12.4%)
$9.81M(+6.5%)
Sep 2002
-
$9.20M(-12.4%)
Jun 2002
-
$10.51M(-1.8%)
Mar 2002
-
$10.70M(-4.5%)
Dec 2001
$11.20M(+43.6%)
$11.20M(+11.8%)
Sep 2001
-
$10.01M(+26.5%)
Jun 2001
-
$7.91M(+6.2%)
Mar 2001
-
$7.45M(-4.4%)
Dec 2000
$7.79M(+85.6%)
$7.79M(+75.2%)
Sep 2000
-
$4.45M(+11.7%)
Jun 2000
-
$3.98M(-10.2%)
Mar 2000
-
$4.43M(+5.5%)
Dec 1999
$4.20M(+44.8%)
$4.20M(+5.0%)
Sep 1999
-
$4.00M(+11.1%)
Jun 1999
-
$3.60M(+24.1%)
Mar 1999
-
$2.90M(0.0%)
Dec 1998
$2.90M(+70.6%)
$2.90M(-6.5%)
Sep 1998
-
$3.10M(+82.4%)
Jun 1998
-
$1.70M(+30.8%)
Mar 1998
-
$1.30M(-23.5%)
Dec 1997
$1.70M(+54.5%)
$1.70M(+54.5%)
Sep 1997
-
$1.10M(0.0%)
Jun 1997
-
$1.10M(-8.3%)
Mar 1997
-
$1.20M(+9.1%)
Dec 1996
$1.10M
$1.10M(-15.4%)
Sep 1996
-
$1.30M(-13.3%)
Jun 1996
-
$1.50M(-11.8%)
Mar 1996
-
$1.70M

FAQ

  • What is Neurocrine Biosciences annual total long term liabilities?
  • What is the all time high annual long term liabilities for Neurocrine Biosciences?
  • What is Neurocrine Biosciences annual long term liabilities year-on-year change?
  • What is Neurocrine Biosciences quarterly total long term liabilities?
  • What is the all time high quarterly long term liabilities for Neurocrine Biosciences?
  • What is Neurocrine Biosciences quarterly long term liabilities year-on-year change?

What is Neurocrine Biosciences annual total long term liabilities?

The current annual long term liabilities of NBIX is $621.30M

What is the all time high annual long term liabilities for Neurocrine Biosciences?

Neurocrine Biosciences all-time high annual total long term liabilities is $621.30M

What is Neurocrine Biosciences annual long term liabilities year-on-year change?

Over the past year, NBIX annual total long term liabilities has changed by +$256.70M (+70.41%)

What is Neurocrine Biosciences quarterly total long term liabilities?

The current quarterly long term liabilities of NBIX is $629.10M

What is the all time high quarterly long term liabilities for Neurocrine Biosciences?

Neurocrine Biosciences all-time high quarterly total long term liabilities is $629.10M

What is Neurocrine Biosciences quarterly long term liabilities year-on-year change?

Over the past year, NBIX quarterly total long term liabilities has changed by +$255.70M (+68.48%)
On this page